AMENDED CLAIMS

1-10. (Canceled)

11. (Currently amended) A parenteral pharmaceutical composition with injection site toleration comprising a therapeutically effective amount of ~~an Active Pharmaceutical Ingredient,~~ a compound of Formula (Ia),



(Ia)

or a pharmaceutically acceptable salt thereof, a β-cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.

12. (Canceled)

13. (Currently amended) The pharmaceutical composition according to Claim [[12]] 11 wherein the β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin or sulfobutyl ether-β-cyclodextrin.

14. (Currently amended) The pharmaceutical composition according to claim [[12]] 13 wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol ~~or a combination thereof~~.

15. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative is about 2.5 to about 3.5 mg/mL of meta-cresol, the cyclodextrin is sulfobutyl ether-β-cyclodextrin, and wherein the pharmaceutically acceptable salt is the citrate monohydrate salt.

16. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative has a binding value to the cyclodextrin that is less than [[a]] the binding value of the ~~Active Pharmaceutical Ingredient~~ compound of Formula (1a) to cyclodextrin.

17-18. (Canceled)

19. (Currently amended) The pharmaceutical composition according to claim 16 wherein the binding value of the ~~Active Pharmaceutical Ingredient~~ compound of Formula (1a) to cyclodextrin is between 800 M^{-1} and ~~31,000~~ 3,000 M^{-1}.

20-28. (Canceled)

29. (New) A pharmaceutical composition comprising about 10 mg/mL of a compound of Formula (la), about 3.3 mg/mL meta-cresol, about 63 mg/mL sulfobutyl ether-β-cyclodextrin, and a pharmaceutically acceptable vehicle.

30. (New) A method for the treatment of emesis in an animal comprising administering to said animal a composition according to Claim 11.